Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 11—November 2023
Research Letter

Tuberculosis Variant with Rifampin Resistance Undetectable by Xpert MTB/RIF, Botswana

Chawangwa Modongo, Ivan Barilar, Qiao Wang, Tuduetso Molefi, Topo Makhondo, Stefan Niemann, and Sanghyuk S. ShinComments to Author 
Author affiliations: Victus Global Botswana Organisation, Gaborone, Botswana (C. Modongo); Forschungszentrum, Borstel, Germany (I. Barilar, S. Niemann); University of California, Irvine, California, USA (Q. Wang, S.S. Shin); University of California, Los Angeles, California, USA (Q. Wang); Botswana Ministry of Health and Wellness, Gaborone (T. Molefi, T. Makhondo); German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany (S. Niemann)

Main Article

Figure

Timeline of events experienced by case-patient in Botswana from study of a rifampin-resistant TB variant not detectable using Xpert MTB/RIF assay (Cepheid, https://www.cepheid.com). Timeline events included routine laboratory procedures, study procedures, and timing of TB treatment. 2HRZ(E)/4HR, standard 6-month tuberculosis treatment regimen (2 months of isoniazid, rifampin and pyrazinamide, with or without ethambutol, followed by 4 months of isoniazid and rifampin); DST, drug susceptibility testing; EMB, ethambutol; INH, isoniazid; LFX, levofloxacin; MDR TB, multidrug-resistant tuberculosis; MFX, moxifloxacin; PZA, pyrazinamide; RMP, rifampin; SM, streptomycin; TB, tuberculosis; WGS, whole-genome sequencing; Xpert, GeneXpert.

Figure. Timeline of events experienced by case-patient in Botswana from study of a rifampin-resistant TB variant not detectable using Xpert MTB/RIF assay (Cepheid, https://www.cepheid.com). Timeline events included routine laboratory procedures, study procedures, and timing of TB treatment. 2HRZ(E)/4HR, standard 6-month tuberculosis treatment regimen (2 months of isoniazid, rifampin and pyrazinamide, with or without ethambutol, followed by 4 months of isoniazid and rifampin); DST, drug susceptibility testing; EMB, ethambutol; INH, isoniazid; LFX, levofloxacin; MDR TB, multidrug-resistant tuberculosis; MFX, moxifloxacin; PZA, pyrazinamide; RMP, rifampin; SM, streptomycin; TB, tuberculosis; WGS, whole-genome sequencing; Xpert, GeneXpert.

Main Article

Page created: September 28, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external